Benzinga | Jan 25, 2021 08:03AM EST

Eiger BioPharmaceuticals Announces US Commercial Availability Of Zokinvy For Progeria And Processing-Deficient Progeroid Laminopathies

PALO ALTO, Calif., Jan. 25, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and availability of Zokinvy(tm) (lonafarnib) in the United States. Zokinvy was approved by the U.S. Food and Drug Administration (FDA) in November 2020 to reduce the risk of death in patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and for the treatment of processing-deficient progeroid laminopathies.